

PERSONAL
INFORMATION

Massimo Federici

POSITION

Professor of Internal Medicine (SC 06/B1 - SSD MED/09)
Department of Systems Medicine
University of Rome Tor Vergata,
Via Montpellier 1, 00133 Rome Italy

EDUCATION
AND TRAININGGraduation:

1988
High School (with honors), Liceo Scientifico A. Righi, Rome, Italy

1994
Medical degree (cum laude), University of Tor Vergata, Rome, Italy

Postdoctoral Training:

1995
Board of Medicine at University of Tor Vergata, Rome, Italy

1996-1997
Research Fellow at Joslin Diabetes Center, Boston USA

1995-1999
Endocrinology and Metabolic Diseases Specialization (Clinical) at

University of Tor Vergata, Rome, Italy

Academic Appointments:

1999-2002

Assistant Professor of Internal Medicine - MED/09 - Department of Internal Medicine, University of Tor Vergata, Rome, Italy

2002- 2006

Associate Professor MED/09 - Department of Internal Medicine, University of Tor Vergata, Rome, Italy

2006-2012

Full Professor MED-F/01 - Department of Internal Medicine, University of Tor Vergata, Rome, Italy

2010-2014

Adjunct Professor of Medicine, Department of Medicine, Division of Diabetes, University of Texas Health Science Center at San Antonio

2013-2018

Professor of Medicine MED/49 (Scienze Tecniche Dietetiche Applicate) Department of Systems Medicine, University of Tor Vergata, Rome, Italy

HEALTH CARE ACTIVITY

2001-2013

Charge of health care activity (art.5 of D. Lgs. 517/99) at the Center of Atherosclerosis "Policlinico Tor Vergata University Hospital", Rome, Italy

2008-2018

Manager of Clinical Program "Center for Atherosclerosis and Medical Day Hospital" (D.D.G. n.10, 06/08/2008) - " Policlinico Tor Vergata University Hospital", Rome, Italy

2018

Direction of UOC Internal Medicine-ambulatory activities - DH - PAC- PDTAs Doctors (DDG n. 232, 03/20/2018), "Policlinico Tor Vergata University Hospital", Rome, Italy

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
ENGLISH	C1	C1	C1	C1	C1

Organization / Managerial Skills 2015-to date
 Coordinator of “Experimental and Systems Medicine” Ph.D. Programme, University of Tor Vergata, Rome, Italy
 2006-to date
 Coordinator in bachelor degree course of “Biotechnology Medical Application”, University of Tor Vergata, Rome, Italy
 2004-to date
 Postgraduate tutorial activity at University of Rome Tor Vergata (phd, specialty in endocrinology, geriatric medicine, internal medicine)
 2016-2017
 Quality Team Member GEV/06 - ANVUR (VQR) 2011-2014
 2017- to date
 Vice Dean of Medicine and Surgery Faculty, University of Tor Vergata, Rome, Italy
 2015
 51st EASD Meeting Program Committee member
 2017-2019
 Member of Scientific Committee of “European Foundation for the Study of Diabetes” and in charge for the Cardiovascular Area
 2017-2019
 Member of Task Force ESC/EASD for 2019 Guidelines CVD/Diabetes

Editorial and peer review scientific activity

2007-to date
Handling Editor di **Acta Diabetologica** (IF 3.4)
2009-2017
Associate Editor di **Atherosclerosis** (IF 4)
2009-2013
Academic Editor di **PlosOne** (IF 4.8)
2009-2013
Editorial Board di **Cell Death and Disease** (IF 4)
2007-2017
Guest Editor di **Cell Death and Differentiation** (IF 9)
2012-2013
Editorial Board di **Diabetes Care** (IF 8)

Peer review for the following journals:

Circulation, JACC, Cell Death and Differentiation, Diabetes, Diabetes Care, ATVB, JCEM, JBC, Stem Cells, Am J Cardiology, Cytokine, Nutr. Met. Card. Dis, Cardiovascular Diabetology, Diab Vasc Dis Res, Cell Death and Disease, Journal of Biological Chemistry, Atherosclerosis, Endocrinology

Grant Auditor

Programma di Ricerca a rilevante interesse nazionale (PRIN) del MIUR
Programma Rientro dei Cervelli del MIUR (call 2008)
French National Research Agency (ANR) (2009/2010/2011): Componente Commissione di Valutazione per settore SVSE/1
European Foundation for the Study of Diabetes (call 2008, call 2013)
Fondazione Ricerca Società Italiana di Diabetologia (call 2008)
Netherlands Organisation for Scientific Research (NWO) (call 2009)
European Commission FP7 call NMP.2011.1.2
NIH DP3 grant applications 2012
Juvenile Diabetes Research Foundation Research calls 2011-2012, 2013-2014, 2015-2016
British Heart Foundation
Program Manager, Cardiovascular Funding Program, EFSD 2017-2019

National and
International
Collaborations

FLORINASH (FP7-HEALTH)

"The role of intestinal microflora in non-alcoholic fatty liver disease

EURHYTHDIA (FP7-HEALTH)

"Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population"

Funded projects in the last years:

2008-2011: TELETHON GRANT GGP08065 "Testing Timp3 as a switch to block metabolic and vascular complications of obesity"

2009-2012: FONDAZIONE ROMA Grant "Transmembrane proteases at the interface of metabolic clues and vascular complications of diabetes"

2011-2013: PRIN/MIUR 2009FATVW3_002 "The role of cluster Mir-216/Mir-217 in metabolic disease"

2012-2014: AIRC IG 13163 "Exploring TIMP3 as potential therapeutic agent in obesity-related hepatocellular carcinoma"

2013-2016: EFSD/LILLY European Research Programme "TIMP3 modulates immune cell microenvironment in a model of metabolic disease"

2014-2016: National Coordinator, PRIN Project prot. 20123BJ89E "Genes, environment and metabolism: predictors, modifiers and markers of vascular aging and cardiometabolic risk"

2014-2017: Juvenile Diabetes Research Foundation grant 1-2007-665 "Role of Regulated Membrane Proteolysis in diabetes vascular complications"

2014-2017: Juvenile Diabetes Research Foundation grant 2014-262 "Modulation of TIMP3/ADAM17 dyad to block Diabetic Nephropathy"

2015-2018: Co-PI Italian Ministry of Health project RF-2011-02349921 "The role of the brain-adipocyte axis activity in potentiating antidepressant efficacy"

2016-2019: Co-PI, PRIN Project prot. 2015MPESJS_004 "Molecular, translational and clinical aspects of age related metabolic diseases"

2019-2021: PRIN Project prot. 2017FM74HK "MICROBESOMICS: effect of gut microbiome on "obesitytypes" in human subjects"

ADDITIONAL INFORMATION

Principal bibliometric index (Scopus) Scopus author ID 7006237353
Documents by author: 198
H-index: 53
Citations index: 10358

Publications Selected publication in the last 10 years:

1. Rizza S, Clementi F, Porzio O, Cardellini M, Savo A, Serino M, Chiricolo G, Romeo F, Lauro R, **Federici M**. Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. *Nutr Metab Cardiovasc Dis*. 2009 Jan;19(1):54-60.
2. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, Tornei F, Bertucci P, Iacobini C, Serino M, Porzio O, Hribal ML, Folli F, Khokha R, Urbani A, Lauro R, Pugliese G, **Federici M**. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology*. 2009 Feb;136:663-72
3. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, **Federici M**, Pricci F, Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. *Arterioscler Thromb Vasc Biol*. 2009 Jun;29(6):831-6.
4. Bellia A, Giardina E, Lauro D, Tesauro M, Di Fede G, Cusumano G, **Federici M**, Rini GB, Novelli G, Lauro R, Sbraccia P. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis*. 2009 Sep;19(7):455-61.
5. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokha R, **Federici M**, Tripathy D, DeFronzo RA, Folli F. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. *Diabetologia*. 2009 Oct;52(10):2169-81.
6. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, **Federici M**.

TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. *Diabetes*. 2009 Oct;58(10):2396-401.

7. Rizza S, Tesaro M, Cardillo C, Galli A, Iantorno M, Gigli F, Sbraccia P, **Federici M**, Quon MJ, Lauro D. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. *Atherosclerosis*. 2009 Oct;206(2):569-74.

8. Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, Vasa-Nicotera M, Ippoliti A, Novelli G, Melino G, Lauro R, **Federici M**. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. *Circulation*. 2009 Oct 13;120(15):1524-32.

9. Rogliani P, Curradi G, Mura M, Lauro D, **Federici M**, Galli A, Saltini C, Cazzola M. Metabolic syndrome and risk of pulmonary involvement. *Resp Med*. 2010 Jan;104(1):47-51.

10. Fiorentino L, Vivanti A, Cavallera M, Marzano V, Ronci M, Fabrizi M, Menini S, Pugliese G, Menghini R, Khokha R, Lauro R, Urbani A, **Federici M**. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. *Hepatology*. 2010 Jan;51(1):103-10.

11. Rizza S, Gigli F, Galli A, Micchelini B, Lauro D, Lauro R, **Federici M**. Adiponectin isoforms in elderly patients with or without coronary artery disease. *J Am Geriatr Soc*. 2010 Apr;58:702-6.

12. Fadini GP, Albiero M, Boscaro E, Menegazzo L, Cabrelle A, Piliego T, **Federici M**, Agostini C, Avogaro A. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. *Cell Biol Int*. 2010 Jul;34(7):709-15.

13. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, **Federici M**, Sibilia M, Blobel CP, Khokha R. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. *J Clin Invest*. 2010 Aug;120(8):2731-44.

14. Rizza S, Cardellini M, Martelli E, Porzio O, Pecchioli C, Nicolucci A, Marx N, Lauro D, Ippoliti A, Romeo F, Lauro R, **Federici M**. Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation. *Atherosclerosis*. 2010 Sep;212(1):316-20.

15. Guglielmi V, D'Adamo M, D'Apice MR, Bellia A, Lauro D, **Federici M**, Lauro R, Novelli G, Sbraccia P. Elbow deformities in a patient with mandibuloacral dysplasia type A. *Am J Med Genet A*. 2010 Nov;152A(11):2711-3.

16. **Federici M**, Menghini R. sPLA2: linking atherosclerosis to aneurysm progression. *Atherosclerosis*. 2011;214:41-2.

17. Mammi C, Pastore D, Lombardo MF, Ferrelli F, Caprio M, Consoli C, Tesauro M, Gatta L, Fini M, **Federici M**, Sbraccia P, Donadel G, Bellia A, Rosano GM, Fabbri A, Lauro D. Sildenafil reduces insulin-resistance in human endothelial cells. PLoS One. 2011 Jan 28;6(1):e14542.
18. Bacci S, Rizza S, Prudente S, Spoto B, Powers C, Facciorusso A, Pacilli A, Lauro D, Testa A, Zhang YY, Di Stolfo G, Mallamaci F, Tripepi G, Xu R, Mangiacotti D, Aucella F, Lauro R, Gervino EV, Hauser TH, Copetti M, De Cosmo S, Pellegrini F, Zoccali C, **Federici M**, Doria A, Trischitta V. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes. 2011 Mar;60(3):1000-7.
19. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, **Federici M**. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis. 2011 Mar;215(1):180-3.
20. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, Gentileschi P, Lauro D, **Federici M**, Lauro R, Sbraccia P. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med. 2011 Mar 25.
21. Rizza S, **Federici M**. Cytokines and metabolic syndrome: the perfect storm for arterial aging. Atherosclerosis. 2011 Apr;215(2):284-5.
22. Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, **Federici M**, Pricci F, Pugliese G. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol. 2011 May;54(5):975-83.
23. Vasa-Nicotera M, Chen H, Tucci P, Yang AL, Saintigny G, Menghini R, Mahè C, Agostini M, Knight RA, Melino G, **Federici M**. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011 Aug;217(2):326-30.
24. Menghini R, **Federici M**. MicroPPARticle in atherosclerosis: guilty or innocent by-standers? Atherosclerosis. 2011 Sep;218(1):21-2.
25. Lombardo MF, De Angelis F, Bova L, Bartolini B, Bertuzzi F, Nano R, Capuani B, Lauro R, **Federici M**, Lauro D, Donadel G. Human placental lactogen (hPL-A) activates signaling pathways linked to cell survival and improves insulin secretion in human pancreatic islets. Islets. 2011 Sep-Oct;3(5):250-8. 2011 Aug;217(2):326-30.
26. Avogaro A, **Federici M**, Betteridge J, Bonadonna R, Campbell IW, Scherthaner GH, Staels B, Farinero E, Crepaldi G. Which is the eligible patient to be treated with pioglitazone? The expert view. J Endocrinol Invest. 2011 Nov;34(10):781-7.

27. Cardellini M, Menghini R, Luzi A, Davato F, Cardolini I, D'Alfonso R, Gentileschi P, Rizza S, Marini MA, Porzio O, Lauro D, Sbraccia P, Lauro R, **Federici M**. Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. *Diabetes*. 2011 Dec;60:3265-70.
28. Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, **Federici M**, Romani M, Napolitano M, Capogrossi MC, Germani A. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. *Diabetologia*. 2012 Jan;55(1):236-44.
29. Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schillaci O, Porzio O, Lauro D, Sbraccia P, Lauro R, **Federici M**. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. *Arterioscler Thromb Vasc Biol*. 2012 Jan;32:74-81.
30. Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, **Federici M**. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. *Diabetes*. 2012 Feb;61(2):454-62.
31. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, Quon MJ, Sbraccia P, **Federici M**, Tesaro M, Cardillo C, Lauro D. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. *Atherosclerosis*. 2012 Jul;223(1):197-203.
32. Rizza S, Copetti M, Cardellini M, Porzio O, Luzi A, Pecchioli C, Martelli E, Valentini A, Ippoliti A, Romeo F, Pellegrini F, Lauro D, Lauro R, **Federici M**. Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. *Atherosclerosis*. 2012 Aug;223(2):448-53.
33. Stoehr R, **Federici M**. Do stem cells cause aging-related intimal medial thickening? *Atherosclerosis*. 2012 Sep;224(1):39-40.
34. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, **Federici M**, Dinsdale D, Knight RA, Melino G, Mak TW. TAp73 depletion accelerates aging through metabolic dysregulation. *Genes Dev*. 2012 Sep 15;26(18):2009-14.
35. Monteleone I, **Federici M**, Sarra M, Franzè E, Casagrande V, Zorzi F, Cavalera M, Rizzo A, Lauro R, Pallone F, MacDonald TT, Monteleone G. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. *Gastroenterology*. 2012 Nov;143(5):1277-87.
36. Bellia A, Marinoni G, D'Adamo M, Guglielmi V, Lombardo M, Donadel G, Gentileschi P, Lauro D, **Federici M**, Lauro R, Sbraccia P. Parathyroid

hormone and insulin resistance in distinct phenotypes of severe obesity: a cross-sectional analysis in middle-aged men and premenopausal women. *J Clin Endocrinol Metab.* 2012 Dec;97(12):4724-32.

37. Bacci S, Prudente S, Copetti M, Spoto B, Rizza S, Baratta R, Di Pietro N, Morini E, Di Paola R, Testa A, Mallamaci F, Tripepi G, Zhang YY, Mercuri L, Di Silvestre S, Lauro R, Malatino L, Consoli A, Pellegrini F, Pandolfi A, Frittitta L, Zoccali C, **Federici M**, Doria A, Trischitta V. Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. *Atherosclerosis.* 2013 Jan;226(1):140-5.

38. Rappa, F, Greco, A, Podrini, C, Cappello, F, Foti, M, Bourgoïn, L, Peyrou, M, Marino, A, Scibetta, N, Williams, R, Mazzoccoli, G, **Federici, M**, Pazienza, V, Vinciguerra, M. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. *PLoS One.* 2013;8(1):e54458. doi: 10.1371/journal.pone.005445

39. Fiorentino L, Cavallera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, Conserva F, Casagrande V, Menghini R, Pontrelli P, Arisi I, D'Onofrio M, Lauro D, Khokha R, Accili D, Pugliese G, Gesualdo L, Lauro R, **Federici M**. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. *EMBO MOLECULAR MEDICINE* 2013 Mar;5(3):441-55

40. Menghini R, Fiorentino L, Casagrande V, Lauro R, **Federici M**. The role of ADAM17 in Metabolic Inflammation. *Atherosclerosis* 2013 6.487May;228(1):12-7.

41. Menghini R, Uccioli L, Vainieri E, Pecchioli C, Casagrande V, Stoehr R, Cardellini M, Porzio O, Rizza S, **Federici M**. Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. *Acta Diabetol.* 2013 Dec;50(6):907-

42. Avogaro A, Vigili de Kreutzenberg S, **Federici M**, Fadini GP. The Endothelium abridges Insulin Resistance to Premature Ageing. *J Am Heart Assoc.* 2013 Jun 21;2(3):e000262

43. Menghini R, Casagrande V, Lauro R, **Federici M**. MicroRNAs in endothelial senescence and atherosclerosis *Journal of Cardiovascular Translational Research* 2013 Dec;6(6):924-30

44. Fiorentino L, Cavallera M, Mavilio M, Conserva F, Menghini R, Gesualdo L, **Federici M**. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. *Acta Diabetol.* 2013 Dec;50(6):965-9.

45. Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, De Bonis C, Marucci A, Goheen E, Prudente S, Morini E, Rizza S, Kanagaki A, Fini G, Mangiacotti D, **Federici M**, De Cosmo S, Pellegrini F, Doria A, Trischitta V. Serum resistin, cardiovascular disease and all-cause

mortality in patients with type 2 diabetes. PLoS One. 2013 Jun 3;8(6):e64729.

46. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, **Federici M**, Gastaldelli A, DeFronzo RA, Folli F. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia. 2013 Oct;56(10):2153-63

47. Stoehr R, **Federici M**. Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. Biochem J. 2013 Aug 15;454(1):1-11

48. Saraceno R, Rizza S, Faleri S, **Federici M**, Nistico SP, Copetti M, Chimenti S. High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patients. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):903-8.

49. Marino A, Menghini R, Fabrizi M, Casagrande V, Mavilio M, Stoehr R, Candi E, Mauriello A, Moreno-Navarrete JM, Gómez-Serrano M, Peral B, Melino G, Lauro R, Fernandez Real JM, **Federici M**. ITC deficiency protects from diet-induced obesity. Diabetes. 2014 Feb;63:550-61.

50. Bellia A, Salli M, Lombardo M, D'Adamo M, Guglielmi V, Tirabasso C, Giordani L, **Federici M**, Lauro D, Foti C, Sbraccia P. Effects of Whole Body Vibration Plus Diet on Insulin-Resistance in Middle-Aged Obese Subjects. Int J Sports Med. 2014 Jun;35(6):511-6.

51. Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, **Federici M**, Van Tassell BW, Zhang S, Abbate A. A NOVEL PHARMACOLOGIC INHIBITOR OF THE NLRP3 INFLAMMASOME LIMITS MYOCARDIAL INJURY FOLLOWING ISCHEMIA-REPERFUSION IN THE MOUSE. J Cardiovasc Pharmacol. 2014 Apr;63(4):316-22.

52. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, **Federici M**, Tripathy D, Folli F. The inflammatory status score including IL-6, TNF- α , osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014 Feb;51(1):123-31.

53. Stöhr R, Marx N, **Federici M**. Tick-tock: Is your cardiometabolic risk on the clock? Diab Vasc Dis Res. 2014 Mar;11(2):66-74.

54. Fabrizi M, Marchetti V, Mavilio M, Marino A, Casagrande V, Cavalera M, Moreno Navarrete JM, Mezza T, Sorice GP, Fiorentino L, Menghini R, Lauro R, Monteleone G, Giaccari A, Fernandez Real JM, **Federici M**. IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in

adipose tissue and systemic insulin sensitivity. *Diabetes*. 2014 Jun;63(6):2086-96.

55. Menghini R, Stöhr R, **Federici M**. MicroRNAs in vascular aging and atherosclerosis. *Ageing Res Rev*. 2014 Mar 27.

56. Menghini R, Casagrande V, Marino A, Marchetti V, Cardellini M, Stoeck R, Rizza S, Martelli E, Greco S, Mauriello A, Ippoliti A, Martelli F, Lauro R, **Federici M**. MiR-216a: a link between endothelial dysfunction and autophagy. *Cell Death Dis*. 2014 Jan 30;5:e1029.

57. Rizza S, Copetti M, Rossi C, Cianfarani MA, Zucchelli M, Luzi A, Pecchioli C, Porzio O, Di Cola G, Urbani A, Pellegrini F, **Federici M**. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. *Atherosclerosis*. 2014 Feb;232(2):260-4.

58. Menghini R, Campia U, Tesauro M, Marino A, Rovella V, Rodia G, Schinzari F, Tolusso B, di Daniele N, **Federici M**, Zoli A, Ferraccioli G, Cardillo C. Toll-Like Receptor 4 Mediates Endothelial Cell Activation Through NF- κ B but Is Not Associated with Endothelial Dysfunction in Patients with Rheumatoid Arthritis. *PLoS One*. 2014 Jun 11;9(6):e99053.

59. Stöhr R, Cavalera M, Menini S, Mavilio M, Casagrande V, Rossi C, Urbani A, Cardellini M, Pugliese G, Menghini R, **Federici M**. Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. *Atherosclerosis*. 2014 Jun 4;235(2):438-443

60. Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, **Federici M**, Sconocchia G, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D. Peroxiredoxin 6, a Novel Player in the Pathogenesis of Diabetes. *Diabetes*. 2014 Oct;63(10):3210-20. doi: 10.2337/db14-0144.

61. Ferrelli F, Pastore D, Capuani B, Lombardo MF, Blot-Chabaud M, Coppola A, Basello K, Galli A, Donadel G, Romano M, Caratelli S, Pacifici F, Arriga R, Di Daniele N, Sbraccia P, Sconocchia G, Bellia A, Tesauro M, **Federici M**, Della-Morte D, Lauro D. Serum glucocorticoid inducible kinase (SGK)-1 protects endothelial cells against oxidative stress and apoptosis induced by hyperglycaemia. *Acta Diabetol*. 2015 Feb;52(1):55-64. doi: 10.1007/s00592-014-0600-4

62. Guglielmi V, Maresca L, D'Adamo M, Di Roma M, Lanzillo C, **Federici M**, Lauro D, Preziosi P, Bellia A, Sbraccia P. Age-related different relationships between ectopic adipose tissues and measures of central obesity in sedentary subjects. *PLoS One*. 2014 Jul 22;9(7):e103381.

63. Menzaghi C, Fontana A, Copetti M, Rizza S, Spoto B, Buranasupkajorn P, Tripepi, Marucci A, Bailetti D, Hastings T, Testa A, Mendonca C, Mallamaci F, De Cosmo S, Bacci S, **Federici M**, Doria A, Zoccali C,

Trischitta V. Joint effect of insulin signaling genes on all-cause mortality. *Atherosclerosis*. 2014 Dec;237(2):639-44.

64. Kappel BA, **Federici M**. Can renin inhibition by Aliskiren prove itself in atherosclerosis prevention? *Atherosclerosis*. 2014 Dec;237(2):767-8.

65. Puig J, Blasco G, Daunis-I-Estadella J, Loshuertos E, Codina J, Cuba V, Ortiz R, Xifra G, Ricart W, Pedraza S, **Federici M**, Fernández-Real JM. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity. *Clin Endocrinol (Oxf)*. 2014 Dec 16. doi: 10.1111/cen.12698.

66. Carnevale D, Pallante F, Fardella V, Fardella S, Iacobucci R, **Federici M**, Cifelli G, De Lucia M, Lembo G. The angiogenic factor PIGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension. *Immunity*. 2014 Nov 20;41(5):737-52.

67. **Federici M**. Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome. *Atheroscler Suppl*. 2015 Feb;17:17-22.

68. Rizza S, Copetti M, Cardellini M, Menghini R, Pecchioli C, Luzi A, Di Cola G, Porzio O, Ippoliti A, Romeo F, Pellegrini F, **Federici M**. A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. *Atherosclerosis*. 2015 Apr;239(2):459-64.

69. Capuani B, Della-Morte D, Donadel G, Caratelli S, Bova L, Pastore D, De Canio M, D'Aguanno S, Coppola A, Pacifici F, Arriga R, Bellia A, Ferrelli F, Tesauro M, **Federici M**, Neri A, Bernardini S, Sbraccia P, Di Daniele N, Sconocchia G, Orlandi A, Urbani A, Lauro D. Liver Protein Profiles in Insulin Receptor Knockout Mice Reveal Novel Molecules Involved in the Diabetes Pathophysiology. *Am J Physiol Endocrinol Metab*. 2015 Feb 24;ajpendo.00447.2014. doi: 10.1152/ajpendo.00447.2014.

70. Stöhr R, Mavilio M, Marino A, Casagrande V, Kappel B, Möllmann J, Menghini R, Melino G, **Federici M**. ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice. *Sci Rep*. 2015 Mar 17;5:9023. doi: 10.1038/srep09023.

71. Luzi A, Rizza S, Cardellini M, Pecchioli C, Di Cola G, Davato F, Porzio O, Ippoliti A, Copetti M, **Federici M**. A1c value for diabetes diagnosis in subjects with established cardiovascular disease. *Acta Diabetol*. 2015 Oct;52(5):999-1001. doi: 10.1007/s00592-015-0729-9

72. Lauro D, Pastore D, Capuani B, Pacifici F, Palmirotta R, Abete P, Roselli M, Bellia A, **Federici M**, Di Daniele N, Sbraccia P, Guadagni F, Lauro R, Della-Morte D. Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: a Novel Molecular Target against Age-Related Diseases. *Curr Med Chem*. 2015 Aug 12. [Epub ahead of print] PubMed PMID: 26264924.

73. Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D'Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, **Federici M**, Cinti S, Sbraccia P. Omental adipose tissue fibrosis and insulin resistance in severe obesity. *Nutr Diabetes*. 2015 Aug 10;5:e175. doi: 10.1038/nutd.2015.22. PubMed PMID: 26258766.
74. Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, **Federici M**, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res*. 2016 Feb;19(1):79-89. doi: 10.1089/rej.2015.1726
75. Menghini R, Casagrande V, Cardellini M, Ballanti M, Davato F, Cardolini I, Stoehr R, Fabrizi M, Morelli M, Anemona L, Bernges I, Schwedhelm E, Ippoliti A, Mauriello A, Böger RH, **Federici M**. FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in human endothelial cells and subjects with atherosclerosis. *Atherosclerosis*. 2015 Sep;242(1):230-5.
76. Kappel BA, Marx N, **Federici M**. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. *Nutr Metab Cardiovasc Dis*. 2015;25:697-705.
77. Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, Nordio A, Carbone S, Mauro AG, Das A, Zalavadia AA, Halquist MS, **Federici M**, Van Tassell BW, Zhang S, Abbate A. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. *J Cardiovasc Pharmacol*. 2015 Jul;66(1):1-8.
78. Guglielmi V, D'Adamo M, Bellia A, Ciotto RT, **Federici M**, Lauro D, Sbraccia P. Iron status in obesity: An independent association with metabolic parameters and effect of weight loss. *Nutr Metab Cardiovasc Dis*. 2015 Jun;25(6):541-7.
79. Pastore D, Della-Morte D, Coppola A, Capuani B, Lombardo MF, Pacifici F, Ferrelli F, Arriga R, Mammi C, **Federici M**, Bellia A, Di Daniele N, Tesaro M, Donadel G, Noto D, Sbraccia P, Sconocchia G, Lauro D. SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF- α . *Cell Death Dis*. 2015 Sep 17;6:e1890.
80. Stöhr R, Kappel BA, Carnevale D, Cavallera M, Mavilio M, Arisi I, Fardella V, Cifelli G, Casagrande V, Rizza S, Cattaneo A, Mauriello A, Menghini R, Lembo G, **Federici M**. TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice. *Mol Metab*. 2015 Aug 6;4(10):741-52.
81. Testa A, Prudente S, Leonardis D, Spoto B, Sanguedolce MC, Parlongo RM, Tripepi G, Rizza S, Mallamaci F, **Federici M**, Trischitta V,

Zoccali C. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. *Nutr Metab Cardiovasc Dis*. 2015 Aug 21

82. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356.

83. Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, Magnoni C, Botti E, Casagrande V, **Federici M**, Costanzo A, Fontana L, Testa G, Mostafa FF, Ibrahim SA, Russo MV, Fratoddi I. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. *Colloids Surf B Biointerfaces*. 2016 May 1;141:141-7. doi: 10.1016/j.colsurfb.2016.01.021.

84. Kappel BA, Stöhr R, De Angelis L, Mavilio M, Menghini R, **Federici M**. Posttranslational modulation of FoxO1 contributes to cardiac remodeling in post-ischemic heart failure. *Atherosclerosis*. 2016 Jun;249:148-56. doi: 10.1016/j.atherosclerosis.2016.04.001.

85. Savarese G, D'Amore C, **Federici M**, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. *Int J Cardiol*. 2016 Jun 27;220:595-601. doi: 10.1016/j.ijcard.2016.06.208.

86. Fryk E, Sundelin JP, Strindberg L, Pereira MJ, **Federici M**, Marx N, Nyström FH, Schmelz M, Svensson PA, Eriksson JW, Borén J, Jansson PA. Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. *Metabolism*. 2016 Jul;65(7):998-1006. doi: 10.1016/j.metabol.2016.04.003.

87. Mavilio M, Marchetti V, Fabrizi M, Stöhr R, Marino A, Casagrande V, Fiorentino L, Cardellini M, Kappel B, Monteleone I, Garret C, Mauriello A, Monteleone G, Farcomeni A, Burcelin R, Menghini R, **Federici M**. A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. *Cell Rep*. 2016 Jun 29. pii: S2211-1247(16)30767-7. doi: 10.1016/j.celrep.2016.06.027.

88. Guglielmi V, Bellia A, Pecchioli S, Medea G, Parretti D, Lauro D, Sbraccia P, **Federici M**, Cricelli I, Cricelli C, Lapi F. What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database. *Int J Cardiol*. 2016 Nov 15;223:701-705. doi: 10.1016/j.ijcard.2016.08.269.

89. Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, **Federici M**, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with

liver fibrosis in obese patients: A pilot analysis. *Hepatology*. 2016 Dec;64(6):2015-2027. doi:10.1002/hep.28829.

90. Möllmann J, Kahles F, Lebherz C, Kappel B, Baeck C, Tacke F, Werner C, **Federici M**, Marx N, Lehrke M. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. *Diabetes Obes Metab*. 2016 Dec 5. doi: 10.1111/dom.12839.

91. Bertoli A, Valentini A, Cianfarani MA, Gasbarra E, Tarantino U, **Federici M**. Low FT3: a possible marker of frailty in the elderly. *Clin Interv Aging*. 2017 Feb 10;12:335-341.

92. Guglielmi V, D'Adamo M, Menghini R, Cardellini M, Gentileschi P, **Federici M**, Sbraccia P. MicroRNA 21 is up-regulated in adipose tissue of obese diabetic subjects. *Nutr Healthy Aging*. 2017 Mar 31;4(2):141-145.

93. Cardellini M, Farcomeni A, Ballanti M, Morelli M, Davato F, Cardolini I, Grappasonni G, Rizza S, Guglielmi V, Porzio O, Pecchioli C, Menghini R, Ippoliti A, **Federici M**. C-peptide: A predictor of cardiovascular mortality in subjects with established atherosclerotic disease. *Diab Vasc Dis Res*. 2017 Sep;14(5):395-399. doi: 10.1177/1479164117710446.

94. Bischetti S, Scimeca M, Bonanno E, **Federici M**, Anemona L, Menghini R, Casella S, Cardellini M, Ippoliti A, Mauriello A. Carotid plaque instability is not related to quantity but to elemental composition of calcification. *Nutr Metab Cardiovasc Dis*. 2017 Sep;27(9):768-774. doi: 10.1016/j.numecd.2017.05.006.

95. Casagrande V, Mauriello A, Bischetti S, Mavilio M, **Federici M**, Menghini R. Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma. *Sci Rep*. 2017 Jul 27;7(1):6747. doi:10.1038/s41598-017-06439-x. PubMed PMID: 28751722;

96. Rossi C, Marzano V, Consalvo A, Zucchelli M, Levi Mortera S, Casagrande V, Mavilio M, Sacchetta P, **Federici M**, Menghini R, Urbani A, Ciavardelli D. Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice. *Acta Diabetol*. 2017 Nov 13. doi: 10.1007/s00592-017-1074-y.

97. Moreno-Navarrete JM, Serino M, Blasco-Baque V, Azalbert V, Barton RH, Cardellini M, Latorre J, Ortega F, Sabater-Masdeu M, Burcelin R, Dumas ME, Ricart W, **Federici M**, Fernández-Real JM. Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity. *Mol Nutr Food Res*. 2018 Feb;62(3). doi: 10.1002/mnfr.201700721.

98. Rizza S, Cardellini M, Pichiucchi G, Longo S, Guglielmi V, Tesauro M, Di Cola G, Pecchioli C, **Federici M**. Brachial flow mediated dilation predicts

glycemia worsening in normoglycemic young subjects. *Acta Diabetologica* 2018 ;55:387-389

99. Rovella V, Anemona L, Cardellini M, Scimeca M, Saggini A, Santeusano G, Bonanno E, Montanaro M, Legramante IM, Ippoliti A, Di Daniele N, **Federici M**, Mauriello A. The role of obesity in carotid plaque instability: interaction with age, gender, and cardiovascular risk factors. *Cardiovasc Diabetol.* 2018;17:46.

100. Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, Sovran B, Denis RGP, Dairou J, Cardellini M, Moreno-Navarrete JM, Straub M, Jegou S, McQuitty C, Viel T, Esposito B, Tavitian B, Callebert J, Luquet S, **Federici M**, Fernandez-Real JM, Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. Indoleamine 2-3 dioxygenase shapes microbiota to reduce IL-22 and promote metabolic disease. *Nature Medicine* in press 2018 (NMED-L87930D)

101. Hoyles L*, Fernández-Real JM*, **Federici M***, Serino M, Abbott J, Charpentier J, Heymes C, Latorre Luque J, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez- Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Fougelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R°, Dumas ME° (*co-first author; °co-corresponding author). Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women. *Nature Medicine* in press 2018 (NMED)

102. Valentini A, **Federici M**, Cianfarani MA, Tarantino U, Bertoli A. Frailty and nutritional status in older people: the Mini Nutritional Assessment as a screening tool for the identification of frail subjects. *Clin Interv Aging.* 2018 Jul 13;13:1237-1244.

103. Valentini A, Cianfarani MA, De Meo L, Morabito P, Romanello D, Tarantino U, **Federici M**, Bertoli A. FRAX tool in type 2 diabetic subjects: the use of HbA(1c) in estimating fracture risk. *Acta Diabetol.* 2018 Jul 6. doi: 10.1007/s00592-018-1187-y.

104. Cardellini M, Ballanti M, Davato F, Cardolini I, Guglielmi V, Rizza S, Pecchioli C, Casagrande V, Mavilio M, Porzio O, Legramante JM, Ippoliti A, Farcomeni A, Sbraccia P, Menghini R, Dumas ME, Kappel BA, **Federici M**. 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease. *Atherosclerosis.* 2018 Jun 12. pii:S0021-9150(18)30326-5. doi: 10.1016/j.atherosclerosis.2018.06.014.

105. Cardellini M, Rizza S, Casagrande V, Cardolini I, Ballanti M, Davato F, Porzio O, Canale MP, Legramante JM, Mavilio M, Menghini R, Martelli E, Farcomeni A, **Federici M**. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. *Acta Diabetol.* 2019 Mar;56(3):273-280. doi: 10.1007/s00592-018-1230-z.

106. Rizza S, Cardellini M, Farcomeni A, Morabito P, Romanello D, Di Cola G, Canale MP, **Federici M**. Low Molecular Weight Adiponectin Increases the Mortality Risk in Very Old Patients. *Aging Dis*. 2018 Oct 1;9(5):946-951. doi: 10.14336/AD.2017.1117.
107. Menghini R, **Federici M**. MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver. *EBioMedicine*. 2018 Nov;37:7-8. doi: 10.1016/j.ebiom.2018.10.040.
108. Iacobini C, Pugliese G, Blasetti Fantauzzi C, **Federici M**, Menini S. Metabolically healthy versus metabolically unhealthy obesity. *Metabolism*. 2019 Mar;92:51-60. doi: 10.1016/j.metabol.2018.11.009
109. Porta M, **Federici M**, Secchi A. Tribute to Professor Guido Pozza, founder and first Editor-in-Chief of *Acta Diabetologica*. *Acta Diabetol*. 2019 Jan;56(1):1. doi: 10.1007/s00592-018-1268-y.
110. Menghini R, **Federici M**. MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps? *Diabetes*. 2019 Feb;68(2):268-270.
111. Cardellini M, Rovella V, Scimeca M, Anemona L, Bischetti S, Casella S, Saggini A, Bonanno E, Ballanti M, Davato F, Menghini R, Ippoliti A, Santeusano G, Di Daniele N, **Federici M**, Mauriello A. Chronic Kidney Disease Is Linked to Carotid Nodular Calcification, An Unstable Plaque Not Correlated to Inflammation. *Aging Dis*. 2019 Feb 1;10(1):71-81. doi: 10.14336/AD.2018.0117.
112. Fratoddi I, Benassi L, Botti E, Vaschieri C, Venditti I, Bessar H, Samir MA, Azzoni P, Magnoni C, Costanzo A, Casagrande V, **Federici M**, Bianchi L, Pellacani G. Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model. *Nanomedicine*. 2019 Jan 30;17:276-286. doi: 10.1016/j.nano.2019.01.006.
113. Laudisi F, Di Fusco D, Dinallo V, Stolfi C, Di Grazia A, Marafini I, Colantoni A, Ortenzi A, Alteri C, Guerrieri F, Mavilio M, Ceccherini-Silberstein F, **Federici M**, MacDonald TT, Monteleone I, Monteleone G. The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation. *Cell Mol Gastroenterol Hepatol*. 2019;7(2):457-473. doi: 10.1016/j.jcmgh.2018.09.002.
114. **Federici M**. Gut microbiome and microbial metabolites: a new system affecting metabolic disorders. *J Endocrinol Invest*. 2019 Feb 20. doi: 10.1007/s40618-019-01022-9.
115. **Federici M**. Our second genome and the impact on metabolic disorders: why gut microbiome is an important player in diabetes and associated abnormalities. *Acta Diabetol*. 2019 May;56(5):491-492. doi: 10.1007/s00592-019-01315-8.

116. Casagrande V, Mauriello A, Anemona L, Mavilio M, Iuliani G, De Angelis L, D'Onofrio M, Arisi I, **Federici M**, Menghini R. Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice. *Acta Diabetol.* 2019 Dec;56(12):1265-1274.
117. Versaci F, Biondi-Zoccai G, Giudici AD, Mariano E, Trivisonno A, Sciarretta S, Valenti V, Peruzzi M, Cavarretta E, Frati G, Scappaticci M, Federici M, Romeo F. Climate changes and ST-elevation myocardial infarction treated with primary percutaneous coronary angioplasty. *Int J Cardiol.* 2019 Nov 1;294:1-5.
118. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2020 Jan 7;41(2):255-323.
119. Rizza S, Neri A, Capanna A, Grecuccio C, Pietroiusti A, Magrini A, Federici M, Coppeta L. Night Shift Working Is Associated With an Increased Risk of Thyroid Nodules. *J Occup Environ Med.* 2020 Jan;62(1):1-3.
120. Valentini A, Cianfarani MA, Federici M, Tarantino U, Bertoli A. Osteoprotegerin in diabetic osteopathy. *Nutr Metab Cardiovasc Dis.* 2020 Jan 3;30(1):49-55.
121. Menghini R, Casagrande V, Iuliani G, Rizza S, Mavilio M, Cardellini M, Federici M. Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target? *Int J Biochem Cell Biol.* 2020 Jan;118:105659.
122. Kappel BA, Federici M. Gut microbiome and cardiometabolic risk. *Rev Endocr Metab Disord.* 2019 Dec;20(4):399-406.
123. Fernández-Real JM, Federici M, Burcelin R. Consider the microbiome in the equation! They were here before us...and hosted us! *Rev Endocr Metab Disord.* 2019 Dec;20(4):383-385.
124. Turchi R, Tortolici F, Guidobaldi G, Iacovelli F, Falconi M, Rufini S, Faraonio R, Casagrande V, Federici M, De Angelis L, Carotti S, Francesconi M, Zingariello M, Morini S, Bernardini R, Mattei M, La Rosa P, Piemonte F, Lettieri-Barbato D, Aquilano K. Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue. *Cell Death Dis.* 2020 Jan 23;11(1):51.
125. Rizza S, Rossini V, Cardellini M, Luzi A, Longo S, Piciucchi G, Coppeta L, Federici M. Diabetes influences cancer risk in patients with

increased carotid atherosclerosis burden. *Nutr Metab Cardiovasc Dis*. 2020 Apr 12;30(4):652-655.

126. Mayneris-Perxachs J, Puig J, Burcelin R, Dumas ME, Barton RH, Hoyles L, Federici M, Fernández-Real JM. The APOA1bp-SREBF-NOTCH axis is associated with reduced atherosclerosis risk in morbidly obese patients. *Clin Nutr*. 2020 Mar 8:S0261-5614(20)30098-4.

127. Martelli E, Federici M. Venous distal bypass should be considered as the gold standard to finally attempt limb salvage in patients with severe critical limb ischemia and diabetic foot, or under dialysis. *Acta Diabetol*. 2020 Apr 3. doi: 10.1007/s00592-020-01524-6.

128. Kappel BA, De Angelis L, Heiser M, Ballanti M, Stoehr R, Goettsch C, Mavilio M, Artati A, Paoluzi OA, Adamski J, Mingrone G, Staels B, Burcelin R, Monteleone G, Menghini R, Marx N, Federici M. Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. *Mol Metab*. 2020 Jun;36:100976.

129. Lombardo M, Perrone MA, Aulisa G, Pellegrini P, Padua E, Bellia C, Annino G, Bellia A, Federici M, Iellamo F. Diet high in protein-rich foods with structured sport activity may be useless to lose fat mass and maintain fat-free mass. *Minerva Gastroenterol Dietol*. 2020 Apr 23.

130. Biondi-Zoccai G, Frati G, Gaspardone A, Mariano E, Di Giosa AD, Bolignano A, Dei Giudici A, Calcagno S, Scappaticci M, Sciarretta S, Valenti V, Casati R, Visconti G, Penco M, Giannico MB, Peruzzi M, Cavarretta E, Budassi S, Cosma J, Federici M, Roeber L, Romeo F, Versaci F. Impact of environmental pollution and weather changes on the incidence of ST-elevation myocardial infarction. *Eur J Prev Cardiol*. 2020 Jun 2:2047487320928450.

131. Ora J, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M, Sergiacomi G, Federici M, Rogliani P. Does bronchoscopy help the diagnosis in Covid-19 infection? *Eur Respir J*. 2020 Jun 11:2001619.

International and
National Trials

ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799.

LIPIGEN Group. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001.

LIPIGEN Group. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.

MEMBERS OF THE LIPIGEN STEERING COMMITTEE; PRINCIPAL INVESTIGATORS: Coordinator center; Participant Centers; Participant Laboratories; COLLABORATORS; STUDY CENTRAL LABORATORY AND ANALYSIS GROUP. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis. 2018 Oct;277:413-418. doi: 10.1016/j.atherosclerosis.2018.08.013.

In compliance with the Italian legislation Decree no 196 dated 30/06/2003 I hereby authorize you to use and process my personal details contained in this document. Personal data protection code and GDPR "General Data Protection Regulation"(Regulation UE n. 2016/679).

Rome, 22/6/2020

Massimo Federici

